Revolution Medicines (RVMD) Stock Forecast & Price Target

Compare

432 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RVMD Analyst Ratings

Strong Buy

15 Buy

0 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Revolution

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RVMD Stock 12 Month Forecast

Average Price Target

$71.24

▲(59.37% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $71.24 with a high forecast of $80.00 and a low forecast of $37.91. The average price target represents a 59.37% change from the last price of $44.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","81":"$81","44.25":"$44.3","56.5":"$56.5","68.75":"$68.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$37.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,44.25,56.5,68.75,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.53,42.643076923076926,45.75615384615385,48.86923076923077,51.98230769230769,55.09538461538462,58.208461538461535,61.32153846153846,64.43461538461538,67.5476923076923,70.66076923076923,73.77384615384615,76.88692307692307,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.53,41.96923076923077,44.40846153846154,46.847692307692306,49.286923076923074,51.72615384615384,54.16538461538461,56.604615384615386,59.04384615384615,61.48307692307692,63.92230769230768,66.36153846153846,68.80076923076922,{"y":71.24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.53,39.40538461538462,39.28076923076923,39.15615384615385,39.03153846153846,38.90692307692308,38.78230769230769,38.65769230769231,38.53307692307692,38.40846153846154,38.28384615384615,38.15923076923077,38.03461538461538,{"y":37.91,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.17,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.8,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.95,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.74,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.65,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.89,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$80.00

Average Price Target$71.24

Lowest Price Target$37.91

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sean McCutcheon

Raymond James

$72

Buy

61.07%

Upside

Initiated

09/12/25

Revolution Medicines resumed with a Strong Buy at Raymond JamesRevolution Medicines resumed with a Strong Buy at Raymond James

Ami Fadia

Needham

$56→$66

Buy

47.65%

Upside

Reiterated

09/11/25

Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution MedicinesRevolution Medicines, Inc. (RVMD) RATING BUY PRICE TARGET $66.00 from $56.00. We increase our estimates for PDAC based on this update and raise our PT to $66.

Eva Fortea Verdejo

Wells Fargo

$67→$70

Buy

56.60%

Upside

Reiterated

09/11/25

Revolution Medicines price target raised to $70 from $67 at Wells FargoRevolution Medicines price target raised to $70 from $67 at Wells Fargo

Kelsey Goodwin

Piper Sandler

$75

Buy

67.79%

Upside

Reiterated

09/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)Daraxonrasib Clinical Update Supports Viable Paths to 1L PDAC; we remain Overweight on RVMD.

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

09/11/25

TD Cowen Keeps Their Buy Rating on Revolution Medicines (RVMD)

Robert Driscoll

Wedbush

$73→$77

Buy

72.26%

Upside

Reiterated

09/11/25

Wedbush Remains a Buy on Revolution Medicines (RVMD)Wedbush analyst Robert Driscoll raised the price target on Revolution (NASDAQ: RVMD) to $77.00 (from $73.00) while maintaining a Outperform rating.

Peter Lawson

Barclays

$72

Buy

61.07%

Upside

Reiterated

09/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: InnovAge Holding (NASDAQ: INNV) and Revolution Medicines (NASDAQ: RVMD)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

09/11/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Travere Therapeutics (TVTX)Encouraging Daraxonrasib Update in PDAC; Phase III Study for 1L mPDAC – Reiterate OP.

Alec Stranahan

Bank of America Securities

$78

Buy

74.50%

Upside

Reiterated

09/11/25

Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT) and Revolution Medicines (NASDAQ: RVMD)

Charles Zhu

LifeSci Capital

$80

Buy

78.97%

Upside

Initiated

09/10/25

Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/09/25

Truist Financial Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Jay Olson

Oppenheimer

$75

Buy

67.79%

Upside

Reiterated

08/25/25

Oppenheimer Sticks to Its Buy Rating for Revolution Medicines (RVMD)Oppenheimer analyst Jay Olson reiterated an Outperform rating and $75.00 price target on Revolution (NASDAQ: RVMD).

Robert Burns

H.C. Wainwright

$72

Buy

61.07%

Upside

Reiterated

08/08/25

H.C. Wainwright Sticks to Its Buy Rating for Revolution Medicines (RVMD)2Q25 Financials Reported; Reiterate Buy – We reiterate our Buy rating and 12‐month price target of $72 per share.

Michael Schmidt

Guggenheim

$80

Buy

78.97%

Upside

Reiterated

08/07/25

Guggenheim Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Andrea Newkirk

Goldman Sachs

$37.91

Buy

-15.19%

Downside

Initiated

07/15/25

Revolution Medicines: Buy Rating Backed by Strategic Focus and Promising Clinical Developments in Precision Oncology

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sean McCutcheon

Raymond James

$72

Buy

61.07%

Upside

Initiated

09/12/25

Revolution Medicines resumed with a Strong Buy at Raymond JamesRevolution Medicines resumed with a Strong Buy at Raymond James

Ami Fadia

Needham

$56→$66

Buy

47.65%

Upside

Reiterated

09/11/25

Eva Fortea Verdejo

Wells Fargo

$67→$70

Buy

56.60%

Upside

Reiterated

09/11/25

Revolution Medicines price target raised to $70 from $67 at Wells FargoRevolution Medicines price target raised to $70 from $67 at Wells Fargo

Kelsey Goodwin

Piper Sandler

$75

Buy

67.79%

Upside

Reiterated

09/11/25

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

09/11/25

TD Cowen Keeps Their Buy Rating on Revolution Medicines (RVMD)

Robert Driscoll

Wedbush

$73→$77

Buy

72.26%

Upside

Reiterated

09/11/25

Wedbush Remains a Buy on Revolution Medicines (RVMD)Wedbush analyst Robert Driscoll raised the price target on Revolution (NASDAQ: RVMD) to $77.00 (from $73.00) while maintaining a Outperform rating.

Peter Lawson

Barclays

$72

Buy

61.07%

Upside

Reiterated

09/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: InnovAge Holding (NASDAQ: INNV) and Revolution Medicines (NASDAQ: RVMD)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

09/11/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Travere Therapeutics (TVTX)Encouraging Daraxonrasib Update in PDAC; Phase III Study for 1L mPDAC – Reiterate OP.

Alec Stranahan

Bank of America Securities

$78

Buy

74.50%

Upside

Reiterated

09/11/25

Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT) and Revolution Medicines (NASDAQ: RVMD)

Charles Zhu

LifeSci Capital

$80

Buy

78.97%

Upside

Initiated

09/10/25

Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/09/25

Truist Financial Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Jay Olson

Oppenheimer

$75

Buy

67.79%

Upside

Reiterated

08/25/25

Oppenheimer Sticks to Its Buy Rating for Revolution Medicines (RVMD)Oppenheimer analyst Jay Olson reiterated an Outperform rating and $75.00 price target on Revolution (NASDAQ: RVMD).

Robert Burns

H.C. Wainwright

$72

Buy

61.07%

Upside

Reiterated

08/08/25

H.C. Wainwright Sticks to Its Buy Rating for Revolution Medicines (RVMD)2Q25 Financials Reported; Reiterate Buy – We reiterate our Buy rating and 12‐month price target of $72 per share.

Michael Schmidt

Guggenheim

$80

Buy

78.97%

Upside

Reiterated

08/07/25

Guggenheim Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Andrea Newkirk

Goldman Sachs

$37.91

Buy

-15.19%

Downside

Initiated

07/15/25

Revolution Medicines: Buy Rating Backed by Strategic Focus and Promising Clinical Developments in Precision Oncology

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

1 Month

xxx

Success Rate

8/15 ratings generated profit

Average Return

+1.05%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +1.05% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+9.67%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +9.67% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

12/18 ratings generated profit

Average Return

+24.77%

reiterated a buy rating last month

Copying Robert Burns's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +24.77% per trade.

2 Years

xxx

Success Rate

14/18 ratings generated profit

Average Return

+38.79%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +38.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVMD Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RVMD has received 32 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RVMD average Analyst price target in the past 3 months is 71.24.

Each month's total comprises the sum of three months' worth of ratings.

RVMD Financial Forecast

RVMD Earnings Forecast

Next quarter’s earnings estimate for RVMD is -$1.39 with a range of -$1.58 to -$1.15. The previous quarter’s EPS was -$1.31. RVMD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.22% of the time in the same period. In the last calendar year RVMD has Preformed in-line its overall industry.

RVMD Sales Forecast

Next quarter’s sales forecast for RVMD is $2.11M with a range of $0.00 to $20.80M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.12% of the time in the same period. In the last calendar year RVMD has Preformed in-line its overall industry.

RVMD Stock Forecast FAQ

What is RVMD’s average 12-month price target, according to analysts?

Based on analyst ratings, Revolution Medicines’s 12-month average price target is 71.24.

What is RVMD’s upside potential, based on the analysts’ average price target?

Revolution Medicines has 59.37% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RVMD a Buy, Sell or Hold?

Revolution Medicines has a consensus rating of Strong Buy which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.

What is Revolution Medicines’s price target?

The average price target for Revolution Medicines is 71.24. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $80.00 ,the lowest forecast is $37.91. The average price target represents 59.37% Increase from the current price of $44.7.

What do analysts say about Revolution Medicines?

Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of RVMD?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Revolution Medicines (RVMD) Stock Forecast & Price Target

RVMD Analyst Ratings

RVMD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revolution Medicines

RVMD Analyst Recommendation Trends

RVMD Financial Forecast

RVMD Earnings Forecast

RVMD Sales Forecast

RVMD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts